Paid Sickle Cell Disease Clinical Trials
Sickle cell disease clinical trials recruiting. Access gene therapies and new treatments. Compensation up to $5,000. Studies for adults and adolescents.
Compensation
$2,500 - $5,000
Duration
52-104 weeks
Phase
Phase I/II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 12-65 years (varies by study)
- Confirmed sickle cell disease (SS, SC, or S-beta thalassemia)
- History of vaso-occlusive crises
- Adequate organ function
- Willingness to use contraception throughout study
- Compliance with current treatment regimen
Who May Not Qualify
- Red blood cell transfusion in past 60 days (for some studies)
- History of stroke
- Iron overload requiring chelation
- Ongoing pregnancy
- Prior stem cell transplant (unless study-specific)
Frequently Asked Questions
What sickle cell treatments are being studied?
+
Studies include gene therapy and gene editing (one-time potentially curative treatments), new medications to prevent sickling, anti-inflammatory treatments, and drugs to reduce vaso-occlusive crises.
What are gene therapy studies like?
+
Gene therapy typically involves collecting your stem cells, genetically modifying them, and reinfusing them after chemotherapy. This is a more intensive process than medication studies and may require extended hospitalization.
How are pain crises tracked during the study?
+
You will maintain a diary of pain episodes, healthcare visits, and treatments. Studies aim to reduce the frequency and severity of vaso-occlusive crises.
Can I continue taking hydroxyurea?
+
Requirements vary by study. Some trials allow stable hydroxyurea, while others require discontinuation. Gene therapy studies typically require stopping disease-modifying medications.